Stevens-Johnson Syndrome Lawsuit

Stevens-Johnson Syndrome (SJS) is a rare but life-threatening skin condition typically caused by adverse reactions to medications. SJS affects 1-2 people per million annually and carries a mortality rate of approximately 5%, rising to 40% when the condition progresses to Toxic Epidermal Necrolysis (TEN). The condition causes severe skin deterioration, blistering, mucosal membrane damage affecting the eyes, mouth, and genitals, and potential internal organ involvement. Common medications associated with SJS include antibiotics (sulfonamides, metronidazole), anticonvulsants (Dilantin, Lamictal, Topamax), NSAIDs (Bextra, Feldene, ibuprofen), and other drug classes. Lawsuits against pharmaceutical manufacturers primarily allege failure to adequately warn consumers and healthcare providers about the severe risks of developing this life-threatening condition.

Litigation outcomes have varied significantly. In 2023, a New Hampshire case resulted in a $21 million verdict for a 51-year-old woman who developed SJS and TEN after taking generic Sulindac, resulting in blindness and permanent damage to her throat, stomach, and lungs. A 2022 Pennsylvania settlement reached $125,000 in an SJS claim case. However, a June 2013 Supreme Court decision overturned a $21.06 million verdict against a pharmaceutical company, making it more difficult to hold generic manufacturers liable in SJS cases. The FDA has issued multiple warnings about medications linked to SJS, including recent warnings about antiseizure medications. Individuals who developed SJS or TEN after taking prescription or over-the-counter medications may qualify to recover compensation for medical expenses, lost wages, pain and suffering, permanent disfigurement, and punitive damages in cases of gross negligence.